These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

783 related items for PubMed ID: 17521292

  • 1. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C, Tsantili-Kakoulidou A, Theocharis S.
    Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
    [Abstract] [Full Text] [Related]

  • 2. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W.
    Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
    [Abstract] [Full Text] [Related]

  • 3. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
    Brown JD, Plutzky J.
    Circulation; 2007 Jan 30; 115(4):518-33. PubMed ID: 17261671
    [Abstract] [Full Text] [Related]

  • 4. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury.
    Collino M, Patel NS, Thiemermann C.
    Ther Adv Cardiovasc Dis; 2008 Jun 30; 2(3):179-97. PubMed ID: 19124421
    [Abstract] [Full Text] [Related]

  • 5. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons.
    Cimini A, Benedetti E, Cristiano L, Sebastiani P, D'Amico MA, D'Angelo B, Di Loreto S.
    Neuroscience; 2005 Jun 30; 130(2):325-37. PubMed ID: 15664689
    [Abstract] [Full Text] [Related]

  • 6. Peroxisome proliferator-activated receptors and the metabolic syndrome.
    Bragt MC, Popeijus HE.
    Physiol Behav; 2008 May 23; 94(2):187-97. PubMed ID: 18191967
    [Abstract] [Full Text] [Related]

  • 7. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
    Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA.
    Arterioscler Thromb Vasc Biol; 2006 Jan 23; 26(1):28-40. PubMed ID: 16239592
    [Abstract] [Full Text] [Related]

  • 8. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD.
    Ann N Y Acad Sci; 2006 Nov 23; 1083():306-18. PubMed ID: 17148746
    [Abstract] [Full Text] [Related]

  • 9. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P, Fruchart JC, Staels B.
    Nat Clin Pract Endocrinol Metab; 2007 Feb 23; 3(2):145-56. PubMed ID: 17237841
    [Abstract] [Full Text] [Related]

  • 10. Peroxisome proliferator-activated receptors and inflammation.
    Moraes LA, Piqueras L, Bishop-Bailey D.
    Pharmacol Ther; 2006 Jun 23; 110(3):371-85. PubMed ID: 16168490
    [Abstract] [Full Text] [Related]

  • 11. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
    Alemán G, Torres N, Tovar AR.
    Rev Invest Clin; 2004 Jun 23; 56(3):351-67. PubMed ID: 15612519
    [Abstract] [Full Text] [Related]

  • 12. Peroxisome proliferator-activated receptors and their relevance to dermatology.
    Friedmann PS, Cooper HL, Healy E.
    Acta Derm Venereol; 2005 Jun 23; 85(3):194-202. PubMed ID: 16040401
    [Abstract] [Full Text] [Related]

  • 13. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH, Roufogalis BD.
    Curr Mol Pharmacol; 2012 Jun 23; 5(2):241-7. PubMed ID: 22122453
    [Abstract] [Full Text] [Related]

  • 14. PPARs as therapeutic targets in cardiovascular disease.
    van Bilsen M, van Nieuwenhoven FA.
    Expert Opin Ther Targets; 2010 Oct 23; 14(10):1029-45. PubMed ID: 20854178
    [Abstract] [Full Text] [Related]

  • 15. [Nuclear Receptor PPARs and magnesium].
    Fujii H.
    Clin Calcium; 2005 Nov 23; 15(11):52-64. PubMed ID: 16272614
    [Abstract] [Full Text] [Related]

  • 16. Peroxisome proliferator-activated receptors and angiogenesis.
    Biscetti F, Straface G, Pitocco D, Zaccardi F, Ghirlanda G, Flex A.
    Nutr Metab Cardiovasc Dis; 2009 Dec 23; 19(11):751-9. PubMed ID: 19628379
    [Abstract] [Full Text] [Related]

  • 17. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer.
    Sertznig P, Seifert M, Tilgen W, Reichrath J.
    J Cell Physiol; 2007 Jul 23; 212(1):1-12. PubMed ID: 17443682
    [Abstract] [Full Text] [Related]

  • 18. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome.
    Guan Y.
    J Am Soc Nephrol; 2004 Nov 23; 15(11):2801-15. PubMed ID: 15504933
    [Abstract] [Full Text] [Related]

  • 19. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling.
    Gardner OS, Dewar BJ, Graves LM.
    Mol Pharmacol; 2005 Oct 23; 68(4):933-41. PubMed ID: 16020742
    [Abstract] [Full Text] [Related]

  • 20. Peroxisome proliferator-activated receptors and inflammation: take it to heart.
    Smeets PJ, Planavila A, van der Vusse GJ, van Bilsen M.
    Acta Physiol (Oxf); 2007 Nov 23; 191(3):171-88. PubMed ID: 17935522
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.